Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Mol Pharm. 2019 Feb 25;16(4):1694–1702. doi: 10.1021/acs.molpharmaceut.9b00025

Figure 2.

Figure 2.

Radioactive HPLC profile of 203Pb-DOTA-GGNle-CycMSHhex (A, TR = 18.3 min) and its mouse serum stability (B) after 4 h incubation at 37 °C. Radioactive HPLC profile of the urine sample of a normal C57 mouse at 2 h post-injection of 203Pb-DOTA-GGNle-CycMSHhex (C). Arrows indicate the original compound of 203Pb-DOTA-GGNle-CycMSHhex. Specific binding of 203Pb-DOTA-GGNle-CycMSHhex on B16/F1 (D) and B16/F10 (E) melanoma cells with or without peptide blockade.